IMVT NASDAQ
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Durham, NY 27713
US
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Stout Jay S | S-Sale | 2,595 | $28.94 | 2026-10-21 |
| Stout Jay S | S-Sale | 2,213 | $32.06 | 2026-10-07 |
| Stout Jay S | S-Sale | 1,596 | $32.06 | 2026-10-07 |
| Van Tuyl Christopher | S-Sale | 1,327 | $32.06 | 2026-10-07 |
| Gloria Melanie | S-Sale | 2,241 | $32.06 | 2026-10-07 |